InsiderTrades.com logo
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.
Volker Knappertz net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Volker Knappertz Biography and Net Worth

Director of GW Pharmaceuticals
Dr. Volker Knappertz is currently the Chief Medical Officer at GW Pharmaceuticals. Dr. Knappertz has over 25 years of clinical trial experience and 17 years of pharmaceutical drug development experience, holding leadership positions with responsibilities for managing international clinical trial and medical affairs programs. Prior to joining GW in May 2017, he served as the Vice President of clinical development for multiple sclerosis, oncology and biosimilar products at Teva Pharmaceuticals. Prior to joining Teva in 2012, Dr. Knappertz served in clinical and medical roles CNS, CV, and biologics at Bayer Pharmaceuticals and AstraZeneca. Dr. Knappertz is a U.S. Board certified neurologist who received his residency training at Yale University in New Haven, Connecticut where he served as chief resident and was fellowship trained at Wake Forest University in Winston-Salem, North Carolina. He received his clinical scientist training and M.D. as well as a doctorate degree in research on glioblastoma from the University at Cologne in Germany.

What is Volker Knappertz's net worth?

The estimated net worth of Volker Knappertz is at least $20.23 million as of March 26th, 2021. Dr. Knappertz owns 92,412 shares of GW Pharmaceuticals stock worth more than $20,234,532 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Knappertz may own. Additionally, Dr. Knappertz receives an annual salary of $830,470.00 as Director at GW Pharmaceuticals. Learn More about Volker Knappertz's net worth.

How old is Volker Knappertz?

Dr. Knappertz is currently 56 years old. There are 4 older executives and no younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is Mr. Douglas B. Snyder, Chief Legal Officer & Sec., who is 57 years old. Learn More on Volker Knappertz's age.

What is Volker Knappertz's salary?

As the Director of GW Pharmaceuticals plc, Dr. Knappertz earns $830,470.00 per year. The highest earning executive at GW Pharmaceuticals is Mr. Justin D. Gover, CEO & Exec. Director, who commands a salary of $1,190,000.00 per year. Learn More on Volker Knappertz's salary.

How do I contact Volker Knappertz?

The corporate mailing address for Dr. Knappertz and other GW Pharmaceuticals executives is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. GW Pharmaceuticals can also be reached via phone at 44-12-2326-6800 and via email at [email protected]. Learn More on Volker Knappertz's contact information.

Has Volker Knappertz been buying or selling shares of GW Pharmaceuticals?

Volker Knappertz has not been actively trading shares of GW Pharmaceuticals during the last quarter. Most recently, Volker Knappertz sold 3,060 shares of the business's stock in a transaction on Friday, March 26th. The shares were sold at an average price of $18.10, for a transaction totalling $55,386.00. Following the completion of the sale, the director now directly owns 92,412 shares of the company's stock, valued at $1,672,657.20. Learn More on Volker Knappertz's trading history.

Who are GW Pharmaceuticals' active insiders?

GW Pharmaceuticals' insider roster includes Cabot Brown (Director), Adam George (Insider), Justin Gover (CEO), Geoffrey Guy (Chairman), Volker Knappertz (Director), Douglas Snyder (Insider), and Christopher Tovey (COO). Learn More on GW Pharmaceuticals' active insiders.

Volker Knappertz Insider Trading History at GW Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2021Sell3,060$18.10$55,386.0092,412View SEC Filing Icon  
1/19/2021Sell6,000$11.67$70,020.0017,940View SEC Filing Icon  
11/24/2020Sell12,000$10.50$126,000.0023,940View SEC Filing Icon  
11/11/2020Sell6,000$10.00$60,000.0035,940View SEC Filing Icon  
11/4/2020Sell6,000$9.17$55,020.0041,940View SEC Filing Icon  
8/4/2020Sell6,000$11.11$66,660.0047,940View SEC Filing Icon  
7/20/2020Sell6,000$11.42$68,520.0053,940View SEC Filing Icon  
6/17/2020Sell18,000$10.35$186,300.00View SEC Filing Icon  
5/15/2020Sell4,296$14.63$62,850.48View SEC Filing Icon  
5/20/2019Sell12,144$14.64$177,788.16View SEC Filing Icon  
2/26/2019Sell4,140$12.46$51,584.409,612View SEC Filing Icon  
See Full Table

Volker Knappertz Buying and Selling Activity at GW Pharmaceuticals

This chart shows Volker Knappertz's buying and selling at GW Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GW Pharmaceuticals Company Overview

GW Pharmaceuticals logo
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $218.96
Low: $218.96
High: $218.96

50 Day Range

MA: $218.59
Low: $216.90
High: $219.28

2 Week Range

Now: $218.96
Low: $87.07
High: $219.57

Volume

N/A

Average Volume

899,771 shs

Market Capitalization

$6.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.